Business Description
NeoGenomics Inc
NAICS : 541714
SIC : 8734
ISIN : US64049M2098
Description
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.59 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.68 | |||||
| Debt-to-EBITDA | -6503.02 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.99 | |||||
| Beneish M-Score | -2.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.9 | |||||
| 3-Year FCF Growth Rate | 29.2 | |||||
| 3-Year Book Growth Rate | -7.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 68.32 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.13 | |||||
| 9-Day RSI | 55.47 | |||||
| 14-Day RSI | 49.76 | |||||
| 3-1 Month Momentum % | -22.14 | |||||
| 6-1 Month Momentum % | -55.83 | |||||
| 12-1 Month Momentum % | -47.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.05 | |||||
| Quick Ratio | 1.95 | |||||
| Cash Ratio | 1.28 | |||||
| Days Inventory | 24.27 | |||||
| Days Sales Outstanding | 80.35 | |||||
| Days Payable | 17.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | -0.18 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.3 | |||||
| Operating Margin % | -12.66 | |||||
| Net Margin % | -11.54 | |||||
| EBITDA Margin % | -0.01 | |||||
| FCF Margin % | -4.81 | |||||
| ROE % | -8.55 | |||||
| ROA % | -4.75 | |||||
| ROIC % | -6.54 | |||||
| 3-Year ROIIC % | 182.81 | |||||
| ROC (Joel Greenblatt) % | -24.77 | |||||
| ROCE % | -5.21 | |||||
| Years of Profitability over Past 10-Year | 3 | |||||
| Moat score | 4 | |||||
| Tariff score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 46.54 | |||||
| PS Ratio | 1.38 | |||||
| PB Ratio | 1.07 | |||||
| Price-to-Tangible-Book | 27.41 | |||||
| Price-to-Operating-Cash-Flow | 121.31 | |||||
| EV-to-EBIT | -16.65 | |||||
| EV-to-EBITDA | -12906.74 | |||||
| EV-to-Revenue | 1.79 | |||||
| EV-to-Forward-Revenue | 2.49 | |||||
| EV-to-FCF | -37.09 | |||||
| Price-to-GF-Value | 0.44 | |||||
| Price-to-Projected-FCF | 4.16 | |||||
| Price-to-Median-PS-Value | 0.36 | |||||
| Earnings Yield (Greenblatt) % | -6.01 | |||||
| FCF Yield % | -3.4 | |||||
| Forward Rate of Return (Yacktman) % | -8.77 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers